Use of becaplermin in the closure of pharyngocutaneous fistulas

Authors

  • David M. Jakubowicz MD,

    1. Department of Otolaryngology, Albert Einstein College of Medicine-Montefiore Medical Center, 3400 Bainbridge Avenue, Bronx, NY 10467
    Current affiliation:
    1. Department of Surgery, Division of Otolaryngology, Maimonides Medical Center, Brooklyn, New York
    Search for more papers by this author
  • Richard V. Smith MD

    Corresponding author
    1. Department of Otolaryngology, Albert Einstein College of Medicine-Montefiore Medical Center, 3400 Bainbridge Avenue, Bronx, NY 10467
    • Department of Otolaryngology, Albert Einstein College of Medicine-Montefiore Medical Center, 3400 Bainbridge Avenue, Bronx, NY 10467
    Search for more papers by this author

Abstract

Background.

We report on the contribution of recombinant platelet-derived growth factor-BB (becaplermin) in treating recalcitrant postlaryngectomy fistulas in two patients with head and neck cancer.

Methods.

Topical becaplermin was applied daily, with periodic wound assessment and photodocumentation.

Results.

The two patients with persistent fistula refractory to conventional management have demonstrated rapid improvement after topical application of becaplermin. Each wound exhibited an exuberant granulation response, with a 50% decrease in the size of wound at 1 week. The patients experienced eventual closure, with none having local recurrence of their cancer at 2 years' follow-up.

Conclusions.

Becaplermin seems to be a promising addition to traditional methods of treatment for postlaryngectomy fistulas. In patients with delayed healing, future studies will be required to determine the overall efficacy of such biologic response modifiers in the treatment of pharyngocutaneous fistulas and other chronic wounds of the head and neck. © 2005 Wiley Periodicals, Inc. Head Neck27: XXX–XXX, 2005

Ancillary